Pharmamarketeer

Novel anti-cancer medicine could improve current therapy for ER+ breast cancer

The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer – the most common form of breast cancer in Australia – according to preclinical studies led by Walter and Eliza Hall Institute researchers.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl